Spinal cord injury (SCI) is a sudden disruption of the spinal cord's neural tissue within the spinal canal, caused by trauma, disease, or degeneration. Thi...
Grifols , a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has finished recruiting the second cohort of...
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapa...
Biogen Inc. and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...
Merck known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved WELIREG® ...
Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for t...
Exelixis, Inc. announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with...
Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) ...
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administe...
Akeso, Inc. is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Admi...
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, reported its consolidated financial results for the fourth quarter and full year ...
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant...
Pfizer Inc. announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)...
Interim analysis of data from the Phase III E.mbrace study (clinical trial identifier: NCT04899336), conducted by an independent data monitoring committee,...
© 2025 Biopharma Boardroom. All Rights Reserved.
